Published Date: 13 Mar 2023
Maharashtra: Maharashtra University of Health Sciences (MUHS) is an affiliated university...
Read Full NewsMarlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.
In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.
A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.
Sphingolipid Profiles May Distinguish IPF from Fibrotic HP
CHEST 2026: Day 1 Recap — 5 Headlines to Know
PAH Combination Therapy and Escalation: Clinical Forum Perspectives
APP Experts Discuss Earlier Biologic Use in Asthma and COPD
1.
Research finds stark disparities in treatment and survival time for people with pancreatic cancer
2.
Enhanced access for patients with prostate cancer is provided by the new SPECT/CT technique, which demonstrates remarkable biomarker identification.
3.
Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus
4.
Surviving cancer, still suffering: Survey reveals gaps in follow‑up care
5.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
1.
Immune Escape Landscapes in Solid Tumors
2.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
3.
Case Study: The Role of Machine Learning in the Detection of Skin Cancer
4.
Reconstruction of Surgical Defects After Cancer Resection
5.
Exercise Programming in Cancer Recovery: Evidence-Based Strategies for Clinical Practice
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
5.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation